Regulation of HMS5552 and metformin on blood glucose and liver glucokinase in type 2 diabetes mellitus rats
10.13699/j.cnki.1001-6821.2018.07.030
- VernacularTitle:比较HMS5552和二甲双胍对2型糖尿病大鼠血糖及肝葡萄糖激酶的调节作用
- Author:
Ying-Li DUAN
1
;
Shou-Min XI
;
Hui-Li LIU
;
Ping WANG
;
Yan-Le ZHANG
;
Ling-Jun MA
;
Xiang-Li SUN
;
Jun-Min FU
Author Information
1. 河南科技大学医学院药理学与医学分子生物学重点实验室
- Keywords:
metformin;
glucokinase;
type 2 diabetes mellitus;
insulin
- From:
The Chinese Journal of Clinical Pharmacology
2018;34(7):834-837
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the regulating effects of metformin and glucokinase activator(HMS5552) on the blood glucose and liver glucokinase in type 2 diabetic rats.Methods The model of type 2 diabetes mellitus was developed by injection of streptozotocin 40 mg · kg-1 combined with high fat sugar diet.After modeling,the experimental group was perfused with 30 mg · kg-1 HMS5552,and the control group was treated with 80 mg· kg-1 metformin,and the normal and model groups were perfused with normal saline.After 4 weeks treatment,the rats were killed after oral glucose tolerance test,heart blood was collected and biochemical detection was performed.The level of liver glucokinase (GCK) was detected by Western blotting.Results After treatment,the blood glucose concentrations of model,control and experimental groups at 60 min and 90 min were (27.27 ± 3.48),(21.47 ± 2.89),(23.67±5.75)mmol · L-1and (33.30 ±4.87),(20.72 ±3.34),(23.13 ±4.02)mmol · L-1;the fasting blood glucose in the three groups were (17.39 ± 1.33),(7.23 ± 0.61),(9.16 ± 1.76)mmol · L-1;the fasting glucagon in the three groups were (152.85 ± 11.42),(64.76 ± 13.62),(64.64 ± 5.30) mmol · L-1.Compared control and experimental groups with model group,the differences of the above indexes were statistically significant (all P ＜ 0.05).Besides,compared control and experimental groups with model group,the differences of the expression of glucokinase protein in liver tissue were statistically significant (all P ＜ 0.05).Conclusion HMS5552 can reduce blood glucose and improve islet beta cell insulin secretion function by enhancing the expression of glucokinase.
